Huynh CN#, Tsai YC#, Tsai MJ, Tsai CJ, Wang CC, Lin CC, Yen YH, Hung CH, Kuo YH, Tai WC, Hu TH, Tsai MC*. Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B. Am J Cancer Res. 2024 Sep 25;14(9):4567-4579. (SCI) 慢性B型肝炎中早期肝細胞癌根治性切除後同時存在MASLD的影響
Tsai YC, Tai WC*, Liang CM, Wu CK, Tsai MC, Hu WH, Huang PY, Chen CH, Kuo YH, Yao CC*, Chuah SK.. Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease. J Microbiol Immunol Infect. 2024 Oct 1:S1684-1182(24)00184-1. doi: 10.1016/j.jmii.2024.09.006. (SCI) 生物製劑治療後腸道微生物群及厚壁菌門/擬桿菌門比例的變化在發炎症性腸病中的研究
Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC*. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol. 2021 Oct 19;21(1):386. (SCI) 術前ALBI分級可預測非B非C肝癌患者接受根除性切除的預後
